|
KMID : 0941820070170020109
|
|
Korean Journal of Clinical Pharmacy
2007 Volume.17 No. 2 p.109 ~ p.116
|
|
|
Drug Use Evaluation of Carbapenem in Korean Hospitalized Patients
|
|
Kim Soo-Jin
Lee Chong-Kil
Lim Sung-Cil
Lee Jun-Seop
Hwang Bang-Yeon
|
|
|
Abstract
|
|
|
|
The carbapenem class such as imipenem (as I), meropenem (as M), and ertapenem(as E), is the most potent and widest spectrum of antimicrobial activity among many structurally distinct β-lactams. The aim of this study is comparatively to evaluate for imipenem, meropenem, versus ertapenem for various infections in a community hospital. This study was performed retrospectively on total 250 cases with I(153), M(88) or E(9) for longer than 3 continuous days at Chungbuk National University Hospital from January 1st thru December 31st, 2005. The major treating microorganisms were E. coli (16.0%), K. pneumoniae (16.0%), A. calcoaceticus-baumannii complex (12.6%), P. aeruginosa (12.0 %) and others (less than 10%), etc. Major diagnoses were sepsis (I26.8%, M63.6% and E33.3%), pneumonia (I35.3% and M13.6%), and intra-abdominal infections (I18.3% and E66.7%), etc and I(5), M(5), and E(4) cases were not met the criteria based on the culture results. In carbapenem monotherapy, the efficacy was I37.3% and M33.0%. All dosage were also appropriate. The mean durations of therapy were all within 14 days. Adverse drug reactions were reported for total 25 cases such as seizure (I4 and M7) or diarrhea (I8, M5, and E1) cases. Uses of carbapenem for inpatient infections were appropriate according to this study and will be recommended in the future.
|
|
|
KEYWORD
|
|
|
carbapenems, drug evaluation, ertapenem, imipenem, meropenem
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|